Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/30/2025

Renal Cancer Screening Guidelines

Introduction to Screening

  • The National Comprehensive Cancer Network recommends screening for individuals with confirmed hereditary RCC syndromes, particularly those with Von Hippel-Lindau (VHL) Disease, using MRI screening (preferred) or CT for surgical planning 1
  • The National Comprehensive Cancer Network also recommends screening for individuals with Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) using annual renal MRI starting at age 8 years 2

Screening for Hereditary Syndromes

  • For individuals with Von Hippel-Lindau (VHL) Disease, the National Comprehensive Cancer Network recommends MRI screening (preferred) or CT for surgical planning, beginning at an appropriate age based on the syndrome 1
  • For individuals with Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), annual renal MRI starting at age 8 years is recommended, using a targeted renal protocol including diffusion-weighted imaging, chemical shift, and gadolinium-based contrast enhanced sequences if lesions are detected 2
  • The National Comprehensive Cancer Network recommends screening for other hereditary syndromes, including BAP1 tumor predisposition syndrome, Birt-Hogg-Dubé syndrome, hereditary papillary renal carcinoma, and tuberous sclerosis, with MRI generally preferred over CT to limit radiation exposure 1

Genetic Evaluation

  • Genetic evaluation should be considered for patients with RCC diagnosis at age ≤46 years, bilateral or multifocal tumors, or ≥1 first or second-degree relative with RCC, according to the National Comprehensive Cancer Network 1
  • Genetic evaluation should also be considered for patients with a family history of renal cell carcinoma, especially with RCC diagnosis at age ≤46 years, bilateral or multifocal tumors, or ≥1 known first- or second-degree relative with RCC, as recommended by the NCCN Guidelines for Kidney Cancer and Genetics in Medicine 1, 3

Screening for Transplant Recipients

  • Most clinical practice guidelines, including the American Journal of Transplantation, do not recommend routine screening for kidney cancer in transplant recipients 4
  • The European Best Practice Guidelines recommend ultrasound screening for native kidney cancer among kidney transplant recipients 4

Imaging Modalities

  • MRI is the preferred screening method for hereditary syndromes, with higher sensitivity for small lesions, no radiation exposure, and better characterization of complex cysts, according to the National Comprehensive Cancer Network 1
  • CT is used primarily for surgical planning or when MRI is contraindicated, with high-quality, multiphase, cross-sectional imaging, and should assess tumor complexity, contrast enhancement, and presence/absence of fat, according to The Journal of Urology 5

Management of Hereditary Syndromes

  • For patients with suspected VHL syndrome, genetic testing for VHL gene mutations and comprehensive imaging with MRI (preferred) or CT for surgical planning are recommended by the NCCN Guidelines for Kidney Cancer 1
  • Regular screening with MRI is recommended to detect early RCC in patients with confirmed VHL syndrome, and nephron-sparing surgery is preferred for renal tumors to preserve kidney function, according to the NCCN Guidelines for Kidney Cancer 1
  • Multidisciplinary management involving urology, oncology, neurology, ophthalmology, and genetics is essential for patients with confirmed VHL syndrome, as stated in the NCCN Guidelines for Kidney Cancer 1

Future Research Directions

  • Research should focus on developing accurate risk prediction models, creating non-invasive methods for early RCC detection, establishing the feasibility and public acceptability of screening, and evaluating potential harms, including impact on quality of life and overdiagnosis, to inform future screening guidelines 1
  • Other hereditary syndromes can also predispose to RCC, including BAP1 tumor predisposition syndrome, Birt-Hogg-Dubé syndrome, Hereditary leiomyomatosis and renal cell cancer, Hereditary papillary renal carcinoma, and Tuberous sclerosis complex, as noted in the NCCN Guidelines for Kidney Cancer 1
  • VHL inactivation is the earliest oncogenic driving event in clear cell RCC development, according to the Nature Reviews Disease Primers 6
  • The VHL gene functions as a tumor suppressor gene, with the VHL protein regulating hypoxia-inducible factors (HIF-1α and HIF-2α), and loss of VHL function leading to aberrant accumulation of HIF proteins, resulting in uncontrolled activation of genes regulating angiogenesis, glycolysis, and apoptosis 6